NA
LLY icon

Navellier & Associates’s Eli Lilly LLY Stock Holding History

Navellier & Associates’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.3M Buy
27,494
+1,507
+6% +$1.53M 2.64% 5
2025
Q4 		$27.9M Sell
25,987
-33
-0.1% -$31.6K 3.13% 2
2025
Q3 		$19.9M Buy
26,020
+1,879
+8% +$1.4M 2.01% 3
2025
Q2 		$18.8M Sell
24,141
-415
-2% -$322K 2.33% 4
2025
Q1 		$20.2M Sell
24,556
-1,442
-6% -$1.2M 2.79% 2
2024
Q4 		$20.1M Buy
25,998
+1,027
+4% +$850K 2.41% 4
2024
Q3 		$22.1M Sell
24,971
-1,728
-6% -$1.55M 3% 3
2024
Q2 		$24.2M Buy
26,699
+1,094
+4% +$875K 2.84% 3
2024
Q1 		$19.9M Buy
25,605
+1,499
+6% +$1.07M 2.45% 4
2023
Q4 		$14.1M Buy
24,106
+2,254
+10% +$1.32M 2.11% 5
2023
Q3 		$11.7M Buy
21,852
+9,125
+72% +$4.7M 2.01% 6
2023
Q2 		$5.97M Sell
12,727
-304
-2% -$127K 1.16% 14
2023
Q1 		$4.48M Sell
13,031
-3,718
-22% -$1.25M 0.94% 25
2022
Q4 		$6.13M Sell
16,749
-858
-5% -$304K 1.25% 15
2022
Q3 		$5.69M Sell
17,607
-367
-2% -$116K 1.27% 16
2022
Q2 		$5.83M Buy
+17,974
New +$5.4M 1.25% 10
2021
Q2 		– Sell
-2,000
Closed -$374K – 327
2021
Q1 		$374K Sell
2,000
-100
-5% -$19.6K 0.07% 209
2020
Q4 		$355K Hold
2,100
– – 0.06% 205
2020
Q3 		$311K Hold
2,100
– – 0.07% 179
2020
Q2 		$345K Sell
2,100
-100
-5% -$15.3K 0.08% 167
2020
Q1 		$305K Buy
2,200
+200
+10% +$27.5K 0.07% 176
2019
Q4 		$263K Buy
2,000
+200
+11% +$23.2K 0.04% 248
2019
Q3 		$201K Sell
1,800
-100
-5% -$11.1K 0.03% 255
2019
Q2 		$211K Buy
1,900
+100
+6% +$11.8K 0.03% 250
2019
Q1 		$234K Sell
1,800
-100
-5% -$12.2K 0.04% 209
2018
Q4 		$220K Sell
1,900
-230
-11% -$25.7K 0.04% 201
2018
Q3 		$229K Sell
2,130
-270
-11% -$27K 0.03% 259
2018
Q2 		$205K Buy
+2,400
New +$197K 0.03% 270
2018
Q1 		– Sell
-3,512
Closed -$297K – 323
2017
Q4 		$297K Sell
3,512
-6,700
-66% -$570K 0.06% 226
2017
Q3 		$874K Sell
10,212
-5,388
-35% -$442K 0.17% 105
2017
Q2 		$1.28M Sell
15,600
-700
-4% -$57.1K 0.19% 127
2017
Q1 		$1.37M Sell
16,300
-500
-3% -$40K 0.2% 121
2016
Q4 		$1.24M Sell
16,800
-800
-5% -$59.6K 0.2% 123
2016
Q3 		$1.41M Sell
17,600
-737
-4% -$59K 0.2% 108
2016
Q2 		$1.44M Buy
18,337
+535
+3% +$40.3K 0.22% 79
2016
Q1 		$1.28M Buy
17,802
+391
+2% +$29.6K 0.17% 77
2015
Q4 		$1.47M Buy
17,411
+3,091
+22% +$257K 0.16% 65
2015
Q3 		$1.2M Buy
14,320
+10,748
+301% +$907K 0.12% 78
2015
Q2 		$298K Buy
+3,572
New +$272K 0.03% 287

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Navellier & Associates's LLY Position: Q1 2026 in Review

Navellier & Associates increased its Eli Lilly (LLY) stake by 5.8% in Q1 2026, buying an estimated $1.53M and bringing the position to 27,494 shares worth $25.3M. The position accounts for 2.64% of the portfolio, ranked #5.

Navellier & Associates first reported a position in LLY in Q2 2015 and has held it in 39 quarters since. The position peaked at $27.9M in Q4 2025. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Navellier & Associates held 27,494 shares of Eli Lilly worth $25.3M as of Q1 2026.
  • Navellier & Associates bought 1,507 Eli Lilly shares in Q1 2026, an estimated $1.53M.
  • Eli Lilly made up 2.64% of Navellier & Associates's portfolio in Q1 2026, its #5 holding.
  • Navellier & Associates first reported a position in Eli Lilly in Q2 2015 and has held it in 39 quarters since.
  • Navellier & Associates's Eli Lilly position peaked at $27.9M in Q4 2025.
  • 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Navellier & Associates's 13F filing for Q1 2026, filed 7 May 2026.